Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Non-cash Items (2019 - 2025)

Tg Therapeutics (TGTX) has 8 years of Non-cash Items data on record, last reported at $96.7 million in Q4 2025.

  • For Q4 2025, Non-cash Items fell 6.77% year-over-year to $96.7 million; the TTM value through Dec 2025 reached $96.7 million, down 6.77%, while the annual FY2025 figure was $96.7 million, 6.77% down from the prior year.
  • Non-cash Items reached $96.7 million in Q4 2025 per TGTX's latest filing, down from $103.7 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $102.5 billion in Q1 2021 and bottomed at $25.1 million in Q4 2022.
  • Average Non-cash Items over 5 years is $17.1 billion, with a median of $72.1 million recorded in 2023.
  • The widest YoY moves for Non-cash Items: up 1020.12% in 2021, down 74.45% in 2021.
  • A 5-year view of Non-cash Items shows it stood at $29.5 million in 2021, then decreased by 15.04% to $25.1 million in 2022, then soared by 89.94% to $47.6 million in 2023, then surged by 117.81% to $103.7 million in 2024, then decreased by 6.77% to $96.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $96.7 million in Q4 2025, $103.7 million in Q4 2024, and $47.6 million in Q4 2023.